CUVL（CUVL）股票分析

$6.520

+0.249 (+3.82%)收盘时

Loading chart…

High: 6.733
Open: 6.290
VWAP: 6.45
Vol: 79.28K
Mkt Cap: —
Low: 6.100
Amount: 511.47K
EV/EBITDA, TTM: 6.50

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.

AI analysis of CUVL (CUVL)

hold

Clinuvel Pharmaceuticals Ltd is not a strong buy right now due to recent poor performance and high volatility. The stock has dropped 20.41% over the last 5 days and 16.64% year-to-date, indicating a bearish trend. Although the forward P/E ratio is 12.95, suggesting potential value, the recent earnings report showed a decline in profit by 6% from the previous year, which raises concerns about future growth.